We propose a new UPCI Shared Resource Facility, entitled the Cancer Biomarkers Facility (CBF), which is motivated by the current and rapidly growing demand from UPCI basic and clinical investigators for integrated and cross-disciplinary biomarker investigations. This shared resource is Cancer Center managed. Recent publications and results from UPCI researchers demonstrate that biomarker research studies, particularly approaches utilizing cutting-edge molecular analysis technological platforms, offer abundant promise for molecular diagnosis and classification of human malignancies. Studies utilizing cutting-edge analytical platforms are expected to rapidly lead to translational applications for improved detection, diagnosis, and prognosis, and for determining efficacy of cancer treatments in patients. The CBF, and its constituent technical platforms, have already provided, and will continue to provide into the next funding period of the UPCI Cancer Center Support Grant (CCSG), clinical applications of state-of-theart systems level molecular profiling that make a major impact on cancer diagnosis, assessment of prognosis, and response to treatment. Accordingly, the mission of the CBF is to provide faculty expertise and collaborative consultation including integrative bioinformatics support across the spectrum of these "omics" technologies, instrumentation, and resources, and together with trained technical staff, to work with UPCI basic and clinical researchers in translational research studies focused on identifying, characterizing, and validating biomarkers for cancer risk prediction, eariy detection and screening, diagnosis, molecular classification/differential diagnosis, prognosis/prediction of disease progression, patient selection/stratification and treatment selection, prediction of therapeutic response, treatment response monitoring/assessment, and metastasis and recurrence prediction and monitoring. The proposed integrated CBF has been established and developed over the current CCSG funding period with sustained investment by UPCI building on the existing strong foundation of established UPCI shared facilities and resident instrumentation and capabilities, together with highly relevant ongoing NCI-funded translational research studies utilizing these resources, including the Eariy Detection Research Network Biomarkers Discovery Laboratory, and the Lung Cancer, Head and Neck Cancer, and Skin Cancer SPORE grants to UPCI faculty investigators. The systems level studies toward identification and validation of novel cancer biomarkers conducted within the CBF are enabled by the following technical platforms presently established and implemented at UPCI: Mass Spectrometry, Microarray, Luminex, and lllumina. Combined with integrated bioinformatics support from the UPCI Cancer Informatics Services (CIS), the CBF provides comprehensive "omics" technology and expertise in a fully integrated systems biology scientific environment to support the basic, clinical, and translational research needs of UPCI investigators.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA047904-26
Application #
8705406
Study Section
Special Emphasis Panel (ZCA1-RTRB-L)
Project Start
Project End
Budget Start
2014-08-01
Budget End
2015-07-31
Support Year
26
Fiscal Year
2014
Total Cost
$266,864
Indirect Cost
$90,326
Name
University of Pittsburgh
Department
Type
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Gross, Neil D; Bauman, Julie E; Gooding, William E et al. (2014) Erlotinib, erlotinib-sulindac versus placebo: a randomized, double-blind, placebo-controlled window trial in operable head and neck cancer. Clin Cancer Res 20:3289-98
Beumer, Jan H; Owzar, Kouros; Lewis, Lionel D et al. (2014) Effect of age on the pharmacokinetics of busulfan in patients undergoing hematopoietic cell transplantation; an alliance study (CALGB 10503, 19808, and 100103). Cancer Chemother Pharmacol 74:927-38
Yang, Liangchun; Xie, Min; Yang, Minghua et al. (2014) PKM2 regulates the Warburg effect and promotes HMGB1 release in sepsis. Nat Commun 5:4436
Zhang, Xuan; Bresee, Jamee; Fields, Gregg B et al. (2014) Near-infrared triple-helical peptide with quenched fluorophores for optical imaging of MMP-2 and MMP-9 proteolytic activity in vivo. Bioorg Med Chem Lett 24:3786-90
Oborski, Matthew J; Demirci, Emre; Laymon, Charles M et al. (2014) Assessment of early therapy response with 18F-FLT PET in glioblastoma multiforme. Clin Nucl Med 39:e431-2
Ng, Yuen-Keng; Lee, Jia-Ying; Supko, Kathryn M et al. (2014) Pan-erbB inhibition potentiates BRAF inhibitors for melanoma treatment. Melanoma Res 24:207-18
Popovtzer, Aron; Normolle, Daniel; Worden, Francis P et al. (2014) Phase I trial of radiotherapy concurrent with twice-weekly gemcitabine for head and neck cancer: translation from preclinical investigations aiming to improve the therapeutic ratio. Transl Oncol 7:479-83
Peterson, Lanell M; Kurland, Brenda F; Schubert, Erin K et al. (2014) A phase 2 study of 16*-[18F]-fluoro-17*-estradiol positron emission tomography (FES-PET) as a marker of hormone sensitivity in metastatic breast cancer (MBC). Mol Imaging Biol 16:431-40
Sun, Xiaofang; Tang, Daolin (2014) HMGB1-dependent and -independent autophagy. Autophagy 10:1873-6
Pollock, Sheri L; Rush, Elizabeth A; Redner, Robert L (2014) NPM-RAR, not the RAR-NPM reciprocal t(5;17)(q35;q21) acute promyelocytic leukemia fusion protein, inhibits myeloid differentiation. Leuk Lymphoma 55:1383-7

Showing the most recent 10 out of 463 publications